Table 1.
Demographic and clinical characteristics of the five cohorts included in the study.
| Characteristic | Cohort 1: IQVIA (ATTR-CM) | Cohort 2: Optum (ATTR-CM) | Cohort 3: IQVIA (cardiac amyloid) | Cohort 4: Optum (cardiac amyloid) | Cohort 5: NMEDW* (cardiac amyloid) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| ATTRwt-CM + HF (n = 1071) | Non-amyloid HF (n = 1071) | ATTRwt-CM + HF (n = 173) | Non-amyloid HF (n = 173) | Cardiac amyloid + HF (n = 7296) | Non-amyloid HF (n = 7296) | Cardiac amyloid + HF (n = 1943) | Non-amyloid HF (n = 1943) | Cardiac amyloid + HF (n = 261) | Non-amyloid HF (n = 39,393) | |
| Age, years | 77 ± 7 | 77 ± 7 | 77 ± 8 | 74 ± 11 | 78 ± 8 | 77 ± 8 | 78 ± 9 | 77 ± 11 | 74 ± 9 | 72 ± 11 |
| Male | 84% | 84% | 82% | 81% | 67% | 67% | 68% | 69% | 69% | 56% |
| Ethnicitya | ||||||||||
| White | — | — | 66% | 80% | — | — | 72% | 80% | 54% | 71% |
| Black | — | — | 28% | 11% | — | — | 22% | 10% | 32% | 13% |
| Other | — | — | 6% | 9% | — | — | 6% | 10% | 14% | 16% |
| Location of final visit | ||||||||||
| Midwest | 28% | 20% | 47% | 48% | 24% | 21% | 49% | 49% | 100% | 100% |
| Northeast | 27% | 20% | 25% | 16% | 28% | 19% | 22% | 11% | 0% | 0% |
| South | 25% | 40% | 20% | 29% | 28% | 39% | 19% | 28% | 0% | 0% |
| West | 18% | 18% | 5% | 5% | 19% | 19% | 6% | 9% | 0% | 0% |
| Other/unknown | 1% | 2% | 3% | 2% | 1% | 1% | 3% | 4% | 0% | 0% |
| Comorbidities | ||||||||||
| Hypertension | 90% | 96% | 83% | 88% | 89% | 92% | 81% | 86% | 72% | 78% |
| Obesity | 42% | 48% | 48% | 47% | 37% | 42% | 34% | 39% | 21% | 25% |
| Diabetes | 42% | 62% | 35% | 52% | 45% | 55% | 39% | 50% | 38% | 36% |
| CAD | 64% | 73% | 54% | 68% | 60% | 65% | 59% | 65% | 56% | 54% |
| CKD | 61% | 44% | 58% | 47% | 52% | 42% | 56% | 43% | 47% | 29% |
| Atrial fibrillation | 72% | 52% | 65% | 52% | 64% | 50% | 61% | 50% | 56% | 41% |
| Diagnosis history duration, yearsb | 9.6 (6.2–10.4) | 9.7 (6.3–10.5) | 6.2 (2.8–9.8) | 6.4 (3.0–9.5) | 8.7 (6.0–10.2) | 8.7 (6.0–10.2) | 5.2 (2.5–8.3) | 5.4 (2.7–8.2) | 6.2 (1.2–15.7) | 4.6 (0.9–10.1) |
| Number of visitsb | 129 (82–210) | 131 (87–205) | 79 (34–187) | 76 (31–168) | 117 (63–193) | 112 (60–187) | 67 (25–141) | 66 (24–140) | 37 (9–99) | 21 (6–60) |
T-tests (for age), Wilcoxon rank-sum tests (for diagnosis history duration and number of visits), and χ2-tests (for categorical variables) were used to compare groups. P-values are two-sided. Adjustments were not made for multiple comparisons.
ATTRwt-CM wild-type amyloidogenic transthyretin cardiomyopathy, CAD coronary artery disease, CKD chronic kidney disease, NMEDW Northwestern Memorial Enterprise Data Warehouse.
aEthnicity data were not available in the IQVIA data.
bMedian (25th–75th percentile).
*P < 0.001 for age, sex, ethnicity, CKD, AF, diagnosis history, and number of visits, and P = 0.015 for hypertension for differences between cardiac amyloid and non-amyloid HF in the NMEDW cohort.